Founder & Managing Director

• Feb 2016 - Present

I founded this management consulting boutique to deliver bespoke projects in healthcare, focused on execution. Areas of practice include interim management, strategic planning, business development, go-to-market studies, start-ups, new technologies in healthcare, and family business.‬‬‬‬ ‬‬‬‬‬‬Key projects include: ◼️Top 10 Swiss Biotech MNC (Venezuela): Engaged to lead strategic planning including delivering modular market re-entry scenarios. ◼️French Biotech (Mexico): led long term planning, strategy alignment and new product launch. ◼️US Biotech (Latam): delivered go-to-market analysis including a business plan to take over out licensed portfolio from partners. ◼️US Med Tech and Pharma companies (Mexico): delivered ideal portfolio strategy and pricing. ◼️Swiss Pharma Group (Latam): led M&A activities, scouting for potential asset targets. ◼️NASDAQ listed Pharma Group (Mexico): delivered commercial due diligence for two M&A targets (deal value of >USD$350m). ◼️Family-owned Pharma Group (Latam): delivered corporate governance and critical SOPs. Show less

Interim Managing Director

• May 2016 - Nov 2020

I was engaged by this start-up to lead the Mexican affiliate incorporation, constituting legal entity, obtaining marketing authorisation, leading successful market access and building specialized professional team of Medical Scientific Liaison (MSL). This role had a strong general management focus on regulatory affairs, market access and commercial leadership. Key achievements include: ◼️Drove significant revenue growth, with CAGR of 100%. ◼️Led market access / new product launch activities including commercial introduction of 5 new products. ◼️Proactively adapted business model during Covid-19 pandemic from face-to-face to remote scientific detailing and webinars, moving administrative personnel to home office. Show less

General Director

• Nov 2013 - Feb 2016

I took overall general management responsibility, leading Mexican affiliate of Stendhal with US$ 170M in revenue, 210 employees. Accountable for Group’s R&D department as well as manufacturing plant. Key achievements include: ◼️Led exponential business growth of 30+%. ◼️Achieved market leadership (70+% market share) of HIV franchise and maximizing anti-infective and multiple sclerosis franchises, in-licensed from Gilead and Biogen. ◼️Led market access and new product launch including national formulary, commercial introduction for antifungal and multiple sclerosis. Also, prepared launch of Helsinn oncology franchise. ◼️Led start-up establishment of Gilead hepatitis C (Sofosbuvir, Ledipasvir + Sofosbuvir) business. ◼️Achieved ‘2014 Great Place to Work’ top ranking in Mexico. Show less

CEO

• Apr 2012 - Oct 2013

I took this CEO position with a focus on strategic planning, business development, restructuring. Transformed from family business to PE-owned multinational group with IFRS consolidated holdings in Spain. Key achievements include: ◼️Optimised licensed and own portfolio focused on oncology, haematology, vaccines and niche / orphan diseases as well as specialty products in gastroenterology, cardiology, respiratory and pain. ◼️Drove license management activities, representing CSL Behring, Actelion, Gilead, Green Cross, Menarini, Ferrer, Cipla, Emcure, Aspen. ◼️Led new business development and exponential revenue growth of 30% per year. ◼️Drove M&A activities, achieving geographic expansion to Brazil with the acquisition of United Medical. Show less

Regional President

• Dec 2008 - May 2011

I was promoted into Regional President role to launch established products (off-patent, generic, OTC) business unit in Europe. Full P&L leadership in Southern and Central Europe (Italy, France, Spain, Portugal, Greece, Belgium, Luxemburg, Austria, Ireland) with turnover of US$1.6B and 1,500 employees. I was a member of European Management team, Worldwide Established Products Leadership team and Pfizer Senior Leadership Council. Key achievements include:◼️Improved revenue erosion in 2009 to -11% from -27% in 2008. Stabilized business to -9% in 2010. ◼️Launched 11 second brands and 60+ generic brands, driving brand value maximization. Also, developed loss of exclusivity strategies for R&D brands including Lipitor. ◼️Responsible for the European integration of pharma company Wyeth in 2009. ◼️Led “Vision & Transformation 2012” restructuring initiative to adapt to financial crisis.◼️Achieved world class 75th percentile Gallup engagement scores. Show less

Country Manager

• Aug 2006 - Nov 2008

Business Unit Director

• Jul 2004 - Aug 2006

Led largest Business Unit US$40M in revenue and 150 employees (five direct, 145 indirect, six Marketing, 141 Field Force). Marketed and sold Cardiovascular / Metabolic (Lipitor, Norvasc, Caduet, Accupril, Aldactone, Lopid), Pain (Celebrex, Bextra, Dynastat, Neurontin, Lyrica) and CNS (Zoloft, Xanax, Geodon, Halcion) franchises. P&L accountability. Product Launches. Launched several products / line extensions that drove corporate success, including Lyrica, Caduet, Xanax XR. Franchise Consolidation. Effectively managed complexity and leveraged Pfizer and Pharmacia portfolios, while consolidating Primary Care franchise after integration of Pharmacia. Crisis Management. Implemented Field Force re-deployment, flexibly re-allocating resources, and coordinated COX-2 (Bextra / Dynastat) team during COX-2 product withdrawal. Gained in-depth experience in crisis management. Show less

Marketing Director

• May 2002 - Jun 2004

Marketing direction for all Rx, Hospital and OTC products (Viagra, Lipitor, COX-2, Cardiovascular, CNS, Antibiotics, Respiratory). Led Pharmacia Country Integration Team with P&L responsibility for 120 brands (40 in promotion through 15 sales lines). Accountable for US$110M in sales. Managed five direct and 25 indirect reports. Product Launch. Orchestrated launch of Atamel Plus and Atamel Forte (OTC Paracetamol line extensions), including media plan and Direct to Consumer strategies, boosting double digit sales of pain market leading brand.Market Share & Product Top Rankings. Established Pfizer as #1 pharmaceutical corporation with 10% market share and top four products of Venezuelan market in June, 2003. Show less

Marketing Manager

• Aug 1999 - May 2002

Planned, executed, and managed marketing initiatives for Rx and hospital products. Led department of 24 employees. Accountable for US$40M in revenue. Turnaround & Growth. Led commercial turnaround and 40+% growth of affiliate in two years. Product Launch Strategy Redesign. Changed strategic approach and resource allocation, launched Dilatrend (Carvedilol) in Heart Failure indication within three weeks to maximize product acceptance and build brand equity. Brand Revitalization. Revitalized dormant, older brands (e.g., Lexotanil, Rivotril) by reviving marketing strategies, achieving significant growth boost. Key Partnership. Negotiated and led partnership with Baxter to commercialize Rocephin (Ceftriaxone) and Baxter infusion bag combo. Show less

General Manager Farma Export

• Jan 1995 - Mar 1999

Founded, developed, and managed import / export center in Panama City, which served as basis to start commercial operations in Central America, Caribbean and Andean Countries. Business Start-up & Growth. Transitioned import / export center from start-up to full scale operation and reached US$12M in revenue in three years. Formulated and implemented business plan for launching Farma Export in Andean Countries, Central America, and Dominican Republic. Evaluated distributors and coordinated trademark and sanitary registrations. Established, launched, and managed operation of Respiratory, Pediatric and Hospital products from Astra Sweden (now Astra Zeneca) and Farma Group. Show less

Director Exports

• Jan 1994 - Dec 1994

Assistant to the President, CFO

• Oct 1992 - Dec 1993

Management Consultant

• Apr 1990 - Oct 1992